Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picankibart in Moderate-to-Severe Plaque Psoriasis
NCT05645627Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of picankibart in plaque psoriasis (3 arms), sponsored by Innovent Biologics. Primary endpoints: Proportion of participants achieving Psoriasis Area and Severity Index 90 at 16 weeks and Proportion of participants achieving static Physician's Global Assessment score of Cleared (0) or Minimal (1) at 16 weeks. Started Feb 2023; status: completed.
02
Drugs
picankibart
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05645627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645627.